ORBIMED ADVISORS LLC
Q2 2022 13F-HR Holdings
Net value change ($000)
-648,447
(-10.5%)
New positions
11
Sold out positions
13
Turnover %
11.7%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q1 2022
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| SVA | 349,500 | NEW |
| Turning Point Therapeutics, Inc. | 97,213 | 179.3% |
| Sierra Oncology, Inc. | 45,072 | 71.6% |
| CMPX | 28,545 | 96.3% |
| Seagen Inc. | 25,464 | 26.5% |
| Gracell Biotechnologies Inc. | 24,995 | 136.0% |
| Mersana Therapeutics, Inc. | 22,525 | 117.9% |
| ARGX | 19,963 | 37.3% |
| Biohaven Pharmaceutical Holding Co Ltd. | 19,514 | 22.9% |
| XENE | 19,463 | 92.8% |
Top Reduces (Value $000, Stocks/ETFs)
| SpringWorks Therapeutics, Inc. | -191,821 | -56.4% |
| Theseus Pharmaceuticals, Inc. | -102,250 | -52.0% |
| IOVA | -79,545 | -72.0% |
| DXCM | -76,689 | -100.0% |
| Horizon Therapeutics Public Ltd Co | -62,922 | -27.2% |
| Mirati Therapeutics, Inc. | -60,861 | -45.4% |
| PFE | -58,320 | -28.8% |
| ISRG | -57,350 | -35.6% |
| PMVP | -49,206 | -34.5% |
| GH | -46,107 | -52.5% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
22,700
(0.4% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|